Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost

NCT00490074 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT00490074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00490074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2007
Completion date
October 31, 2009
Enrollment
147 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections